Exalenz Bioscience is collaborating with the Acute Liver Failure Study Group to study the ability of the BreathID Methacetin Breath Test to predict patient outcome in cases of acute liver failure.
GI Dynamics received the initial results from its pivotal clinical trial of the EndoBarrier therapy.
David N. Gill, CFO of EndoChoice, purchased 5,000 shares of the company in a recent transaction.
Timpani Capital Management raised its stake in Cantel Medical by 1.1 percent.
Intercept Pharmaceuticals developed a new research initiative with the University of Pennsylvania’s PennCHOP Microbiome Program to study the effects of obeticholic acid on the microbiome in a number of chronic liver diseases.
More articles on GI/endoscopy:
3 points on the 2016 Gut Microbiota for Health World Summit
Central Illinois Endoscopy Center performs free colonoscopy for veterans
5 key thoughts from Dr. Brian Hudes on GI physician entrepreneurship
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.